三個皮匠報告
政策庫
new
付費
搜索

圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額-行業數據

圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額
經統計，大藥企的創新藥收入中平均約有 3成將在 2030年前面臨專利懸崖，即仿制藥的沖擊。所以大藥企急需通過M&A來填補這一巨大窟窿。
其它 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?93KB 圖片尺寸：2279*741
同報告圖片
 / 70
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第1頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第2頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第3頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第4頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第5頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第6頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第7頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第8頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第9頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第10頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第11頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第12頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第13頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第14頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第15頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第16頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第17頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第18頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第19頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第20頁
55Sx5LqO5oiR5peg5rOV55u05o6l5o+Q5Y+W5Zu+54mH5Lit55qE5pWw5o2u77yM5Zug5q2k6K+35oKo5o+Q5L6b5Zu+54mH5Lit55qE5pWw5o2u77yM5oiR5bCG5Li65oKo55Sf5oiQ5pWw5o2u6KGo5qC844CC
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第21頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第22頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第23頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第24頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第25頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第26頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第27頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第28頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第29頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第30頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第31頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第32頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第33頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第34頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第35頁
fCDoja/niakgICAgICAgICAgICB8IOWJgumHjyAgICAgICB8IFBsYWNlYm8gfCAyOG1nIHwgNTBtZyB8IDE1bWcgfCAzMG1nIHwgMC44ZyB8IDEuMmcgfCA4MG1nIHwgMTAwbWcgfCAxMG1nIHwgMjVtZyB8IDAuMm1nIHwgMC40bWcgfAp8LS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLXwtLS0tLS18LS0tLS0tfC0tLS0tLXwKfCBFZnJ1eGlmZXJtaW4gICAgfCA2NiUgRjMgICAgIHwgMjAlICAgICB8IDM5JSogfCA0MSUqIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8CnwgUGVnemFmZXJtaW4gICAgIHwgNjUlIEYzICAgICB8IDclICAgICAgfCAgICAgIHwgICAgICB8IDIyJSAgfCAyNiUgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfAp8IExhbmlmaWJyYW5vciAgICB8ICUgRjMgTm90IFJlcG9ydGVkIHwgMjklICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAzMiUgIHwgNDYlKiB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8CnwgUmVzbWV0aXJvbSAgICAgIHwgNjIlIEYzICAgICB8IDE0JSAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAyNCUqKiB8IDI2JSoqIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8CnwgT2JldGljaG9saWMgQWNpZHwgNTQlIEYzICAgICB8IDEwJSAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8IDE0JSAgfCAyMiUqKiogfCAgICAgIHwgICAgICB8CnwgU2VtYWdsdXRpZGUgICAgIHwgNjklIEYzICAgICB8IDMzJSAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8ICAgICAgfCAgICAgIHwgICAgICB8IDMyJSAgfCA0MyUgICB8ICAgICAgfCAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVO+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第36頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第37頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第38頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第39頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第40頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第41頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第42頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第43頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第44頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第45頁
fOW5tOS7vXzplIDllK7pop3vvIjnmb7kuIfnvo7ph5HvvIl85aKe6YCffAp8LS0tfC0tLXwtLS18CnwyMDExfDUwfDAlfAp8MjAxMnwxMDB8MTAwJXwKfDIwMTN8MjAwfDEwMCV8CnwyMDE0fDUwMHwxNTAlfAp8MjAxNXwxMDAwfDEwMCV8CnwyMDE2fDEwMDB8MCV8CnwyMDE3fDE1MDB8NTAlfAp8MjAxOHwxNTAwfDAlfAp8MjAxOXwyNTAwfDY2LjY3JXwKfDIwMjB8MzUwMHw0MCV8CnwyMDIxfDQ1MDB8MjguNTclfAp8MjAyMnw3MDAwfDU1LjU2JXwKfDIwMjPlubTliY055pyIfDcwMDB8MCV8CgrotYTmlpnmnaXmupDvvJpTRUPlrpjnvZHvvIzlhazlj7jlhazlkYrvvIzlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaLmlbTnkIY=
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第46頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第47頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第48頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第49頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第50頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第51頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第52頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第53頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第54頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第55頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第56頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第57頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第58頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第59頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第60頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第61頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第62頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第63頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第64頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第65頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第66頁
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
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第67頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第68頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第69頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第70頁
圖2、預計2023-2029年專利到期的大藥企主要創新藥產品及對應的2022年銷售額_第71頁
所屬報告： 醫藥行業美股biotech投資展望：創新和商業化兩條主線凸顯-240224（56頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站